HMX2
gene geneOn this page
Also known as NKX5-2
Summary
HMX2 (H6 family homeobox 2, HGNC:5018) is a protein-coding gene on chromosome 10q26.13, encoding Homeobox protein HMX2 (A2RU54). Transcription factor involved in specification of neuronal cell types and which is required for inner ear and hypothalamus development.
The protein encoded by this gene is a member of the NKL homeobox family of transcription factors. Members in this family are of ancient origin and play an important role in organ development during embryogenesis. A related mouse protein plays a role in patterning of inner ear structures. In humans, variations in a region containing this gene have been associated with inner ear malformations, vestibular dysfunction, and hearing loss.
Source: NCBI Gene 3167 — RefSeq curated summary.
At a glance
- GWAS associations: 1
- Clinical variants (ClinVar): 48 total
- MANE Select transcript:
NM_005519
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:5018 |
| Approved symbol | HMX2 |
| Name | H6 family homeobox 2 |
| Location | 10q26.13 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | NKX5-2 |
| Ensembl gene | ENSG00000188816 |
| Ensembl biotype | protein_coding |
| OMIM | 600647 |
| Entrez | 3167 |
Gene structure
Transcript identifiers
Ensembl transcripts: 1 — 1 protein_coding
ENST00000339992
RefSeq mRNA: 1 — MANE Select: NM_005519
NM_005519
CCDS: CCDS31305
Canonical transcript exons
ENST00000339992 — 2 exons
| Exon | Start | End |
|---|---|---|
| ENSE00001370710 | 123149570 | 123150672 |
| ENSE00001448150 | 123148136 | 123148646 |
Expression profiles
Bgee: expression breadth broad, 28 present calls, max score 73.33.
FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.1482 / max 61.3597, expressed in 22 samples.
FANTOM5 promoters (3 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 107484 | 0.0952 | 15 |
| 107485 | 0.0304 | 8 |
| 107486 | 0.0226 | 8 |
Top tissues by expression
226 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| pancreatic ductal cell | CL:0002079 | 73.33 | silver quality |
| buccal mucosa cell | CL:0002336 | 70.21 | gold quality |
| tibialis anterior | UBERON:0001385 | 65.97 | silver quality |
| kidney epithelium | UBERON:0004819 | 65.12 | gold quality |
| adult mammalian kidney | UBERON:0000082 | 62.19 | gold quality |
| ileal mucosa | UBERON:0000331 | 60.66 | gold quality |
| vena cava | UBERON:0004087 | 58.35 | gold quality |
| epithelial cell of pancreas | CL:0000083 | 56.27 | gold quality |
| mucosa of transverse colon | UBERON:0004991 | 55.75 | gold quality |
| kidney | UBERON:0002113 | 55.13 | gold quality |
| cardiac muscle of right atrium | UBERON:0003379 | 54.34 | gold quality |
| left ventricle myocardium | UBERON:0006566 | 54.23 | gold quality |
| upper arm skin | UBERON:0004263 | 53.52 | gold quality |
| upper leg skin | UBERON:0004262 | 51.25 | gold quality |
| myocardium | UBERON:0002349 | 50.25 | gold quality |
| lower lobe of lung | UBERON:0008949 | 50.03 | silver quality |
| hypothalamus | UBERON:0001898 | 49.63 | gold quality |
| quadriceps femoris | UBERON:0001377 | 47.52 | gold quality |
| nasal cavity epithelium | UBERON:0005384 | 47.03 | gold quality |
| vastus lateralis | UBERON:0001379 | 45.40 | gold quality |
| amniotic fluid | UBERON:0000173 | 44.97 | gold quality |
| layer of synovial tissue | UBERON:0007616 | 43.55 | gold quality |
| skeletal muscle tissue of rectus abdominis | UBERON:0004511 | 43.37 | gold quality |
| superior surface of tongue | UBERON:0007371 | 42.79 | gold quality |
| lower esophagus mucosa | UBERON:0035834 | 42.78 | silver quality |
| jejunum | UBERON:0002115 | 42.73 | gold quality |
| cortex of kidney | UBERON:0001225 | 42.68 | gold quality |
| duodenum | UBERON:0002114 | 42.63 | gold quality |
| secondary oocyte | CL:0000655 | 42.57 | gold quality |
| skin of hip | UBERON:0001554 | 42.50 | silver quality |
Single-cell (SCXA)
Detected in 1 experiment(s), a significant marker in 0.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-ANND-3 | no | 0.65 |
Regulation
Is transcription factor: yes
Downstream targets (CollecTRI)
1 targets.
| Target | Regulation |
|---|---|
| SLC26A9 |
Upstream regulators (CollecTRI, top): HMX3, RBPJ
miRNA regulators (miRDB)
45 targeting HMX2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-5692A | 100.00 | 74.40 | 6850 |
| HSA-MIR-3162-3P | 100.00 | 65.37 | 363 |
| HSA-MIR-5011-5P | 100.00 | 83.46 | 5820 |
| HSA-MIR-4789-3P | 99.99 | 70.75 | 2484 |
| HSA-MIR-6870-5P | 99.99 | 68.55 | 2115 |
| HSA-MIR-548C-3P | 99.99 | 74.01 | 7587 |
| HSA-LET-7F-2-3P | 99.98 | 70.98 | 2588 |
| HSA-MIR-1185-1-3P | 99.98 | 71.04 | 2593 |
| HSA-MIR-1185-2-3P | 99.98 | 71.04 | 2593 |
| HSA-MIR-4723-5P | 99.97 | 68.70 | 2034 |
| HSA-MIR-5698 | 99.97 | 68.49 | 2029 |
| HSA-MIR-7111-5P | 99.97 | 68.48 | 2062 |
| HSA-MIR-493-5P | 99.96 | 72.47 | 2382 |
| HSA-MIR-101-3P | 99.94 | 75.03 | 2230 |
| HSA-MIR-1323 | 99.83 | 69.89 | 2471 |
| HSA-MIR-4307 | 99.82 | 70.45 | 3374 |
| HSA-MIR-1299 | 99.77 | 71.24 | 2389 |
| HSA-MIR-548O-3P | 99.74 | 69.30 | 2228 |
| HSA-MIR-4699-3P | 99.71 | 70.15 | 3142 |
| HSA-MIR-3934-5P | 99.67 | 64.04 | 846 |
| HSA-MIR-466 | 99.67 | 70.85 | 2863 |
| HSA-MIR-4690-5P | 99.65 | 66.24 | 813 |
| HSA-MIR-4666B | 99.64 | 68.69 | 1282 |
| HSA-MIR-1260A | 99.61 | 66.67 | 1098 |
| HSA-MIR-1260B | 99.61 | 66.67 | 1098 |
| HSA-MIR-4643 | 99.49 | 67.63 | 1791 |
| HSA-MIR-5584-5P | 99.49 | 68.22 | 2814 |
| HSA-MIR-223-5P | 99.24 | 68.82 | 1206 |
| HSA-MIR-4717-3P | 99.06 | 66.34 | 1072 |
| HSA-MIR-3190-5P | 98.87 | 64.89 | 1345 |
Literature-anchored findings (GeneRIF, showing 2)
- propose that hemizygous deletions of HMX2 and HMX3 are responsible for inner ear malformations, vestibular dysfunction, and congenital sensorineural hearing loss (PMID:19253379)
- Aberrant expression of NKL homeobox genes HMX2 and HMX3 interferes with cell differentiation in acute myeloid leukemia. (PMID:33048949)
Cross-species orthologs
3 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | hmx2 | ENSDARG00000070954 |
| mus_musculus | Hmx2 | ENSMUSG00000050100 |
| rattus_norvegicus | Hmx2 | ENSRNOG00000020638 |
Paralogs (3): HOXA9 (ENSG00000078399), HMX3 (ENSG00000188620), HMX1 (ENSG00000215612)
Protein
Protein identifiers
Homeobox protein HMX2 — A2RU54 (reviewed: A2RU54)
Alternative names: Homeobox protein H6 family member 2
All UniProt accessions (1): A2RU54
UniProt curated annotations — full annotation on UniProt →
Function. Transcription factor involved in specification of neuronal cell types and which is required for inner ear and hypothalamus development.
Subcellular location. Nucleus.
Similarity. Belongs to the HMX homeobox family.
RefSeq proteins (1): NP_005510* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR001356 | HD | Domain |
| IPR009057 | Homeodomain-like_sf | Homologous_superfamily |
| IPR017970 | Homeobox_CS | Conserved_site |
| IPR020479 | HD_metazoa | Domain |
| IPR051300 | HMX_Homeobox_TF | Family |
Pfam: PF00046
UniProt features (5 total): compositionally biased region 2, chain 1, DNA-binding region 1, region of interest 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-A2RU54-F1 | 65.51 | 0.24 |
Function
Pathways and Gene Ontology
Reactome pathways
0 pathways
MSigDB gene sets: 80 (showing top):
BENPORATH_ES_WITH_H3K27ME3, GOBP_POSITIVE_REGULATION_OF_RNA_SPLICING, GOBP_POSITIVE_REGULATION_OF_MRNA_PROCESSING, GOBP_ANIMAL_ORGAN_MORPHOGENESIS, GOBP_EAR_DEVELOPMENT, KOYAMA_SEMA3B_TARGETS_UP, GOBP_EMBRYONIC_ORGAN_MORPHOGENESIS, GOBP_RNA_SPLICING, GOBP_EAR_MORPHOGENESIS, GOBP_HEAD_DEVELOPMENT, TANAKA_METHYLATED_IN_ESOPHAGEAL_CARCINOMA, GOBP_REGULATION_OF_MRNA_SPLICING_VIA_SPLICEOSOME, GOBP_EMBRYO_DEVELOPMENT, GOBP_SENSORY_ORGAN_DEVELOPMENT, GOBP_SENSORY_ORGAN_MORPHOGENESIS
GO Biological Process (12): regulation of transcription by RNA polymerase II (GO:0006357), brain development (GO:0007420), cell differentiation (GO:0030154), inner ear morphogenesis (GO:0042472), positive regulation of mRNA splicing, via spliceosome (GO:0048026), epithelial cell proliferation (GO:0050673), positive regulation of epithelial cell proliferation (GO:0050679), stem cell proliferation (GO:0072089), positive regulation of stem cell proliferation (GO:2000648), regulation of DNA-templated transcription (GO:0006355), nervous system development (GO:0007399), cell population proliferation (GO:0008283)
GO Molecular Function (4): RNA polymerase II transcription regulatory region sequence-specific DNA binding (GO:0000977), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), sequence-specific double-stranded DNA binding (GO:1990837), DNA binding (GO:0003677)
GO Cellular Component (2): chromatin (GO:0000785), nucleus (GO:0005634)
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| cell population proliferation | 2 |
| positive regulation of cell population proliferation | 2 |
| regulation of DNA-templated transcription | 1 |
| transcription by RNA polymerase II | 1 |
| central nervous system development | 1 |
| animal organ development | 1 |
| head development | 1 |
| cellular developmental process | 1 |
| ear morphogenesis | 1 |
| embryonic morphogenesis | 1 |
| inner ear development | 1 |
| mRNA splicing, via spliceosome | 1 |
| positive regulation of RNA splicing | 1 |
| regulation of mRNA splicing, via spliceosome | 1 |
| positive regulation of mRNA processing | 1 |
| epithelial cell proliferation | 1 |
| regulation of epithelial cell proliferation | 1 |
| stem cell division | 1 |
| stem cell proliferation | 1 |
| regulation of stem cell proliferation | 1 |
| DNA-templated transcription | 1 |
| regulation of gene expression | 1 |
| regulation of RNA biosynthetic process | 1 |
| system development | 1 |
| cellular process | 1 |
| transcription cis-regulatory region binding | 1 |
| chromatin | 1 |
| RNA polymerase II transcription regulatory region sequence-specific DNA binding | 1 |
| DNA-binding transcription factor activity | 1 |
| regulation of transcription by RNA polymerase II | 1 |
| double-stranded DNA binding | 1 |
| sequence-specific DNA binding | 1 |
| nucleic acid binding | 1 |
| chromosome | 1 |
| cellular anatomical structure | 1 |
| intracellular membrane-bounded organelle | 1 |
Protein interactions and networks
STRING
310 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| HMX2 | GAL | P22466 | 687 |
| HMX2 | PAX2 | Q02962 | 617 |
| HMX2 | GHRH | P01286 | 550 |
| HMX2 | NXPH2 | O95156 | 521 |
| HMX2 | GRAMD1B | Q3KR37 | 480 |
| HMX2 | BMP4 | P12644 | 445 |
| HMX2 | LRRC3B | Q96PB8 | 418 |
| HMX2 | GJA9 | P57773 | 395 |
| HMX2 | ZNF560 | Q96MR9 | 380 |
| HMX2 | GJA10 | Q969M2 | 366 |
| HMX2 | CTNNB1 | P35222 | 364 |
| HMX2 | NALF2 | O75949 | 360 |
| HMX2 | CALY | Q9NYX4 | 332 |
| HMX2 | BUB3 | O43684 | 319 |
| HMX2 | GZF1 | Q9H116 | 315 |
IntAct
4 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| STAMBPL1 | psi-mi:“MI:0914”(association) | 0.350 | |
| USP38 | psi-mi:“MI:0914”(association) | 0.350 | |
| HMX2 | CALB2 | psi-mi:“MI:0914”(association) | 0.350 |
BioGRID (6): LHPP (Affinity Capture-MS), CALB2 (Affinity Capture-MS), HMX2 (Affinity Capture-MS), HMX2 (Cross-Linking-MS (XL-MS)), HMX2 (Cross-Linking-MS (XL-MS)), HMX2 (Cross-Linking-MS (XL-MS))
ESM2 similar proteins: A0A1W2PQ73, A1YF16, A1YG93, A2RU54, A5PKG8, O02786, O14813, O15353, O35602, O43638, O57601, P13297, P19419, P28360, P35548, P41969, P42580, P43687, P49640, P50223, P50548, P52946, P52950, P63156, P63157, P70459, P78413, Q03358, Q14549, Q2VL78, Q2VL79, Q2VL82, Q2VL83, Q2VL84, Q2VL85, Q2VL86, Q2VL87, Q2VL88, Q5NSW5, Q61575
Diamond homologs: A1YF16, A1YG93, A2RU54, A2T764, A6NCS4, A6NHT5, G5EE18, M0R6D8, O02786, O35767, O42230, O57601, O60479, O70218, P10181, P13297, P15857, P19601, P20009, P23410, P28360, P28361, P28362, P35548, P35993, P40764, P42580, P42581, P43687, P43688, P48031, P50219, P50223, P50574, P50575, P50576, P50577, P52953, P53547, P53770
SIGNOR signaling
0 interactions.
Disease & clinical
Clinical variants and AI predictions
ClinVar
48 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 44 |
| Likely benign | 3 |
| Benign | 1 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
325 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 10:123148558:G:GT | donor_gain | 1.0000 |
| 10:123148592:GGCCC:G | donor_gain | 1.0000 |
| 10:123148593:GCCC:G | donor_gain | 1.0000 |
| 10:123148559:A:T | donor_gain | 0.9900 |
| 10:123148600:G:GT | donor_gain | 0.9900 |
| 10:123148601:G:GT | donor_gain | 0.9900 |
| 10:123148607:GGCCC:G | donor_gain | 0.9900 |
| 10:123149560:C:A | acceptor_gain | 0.9900 |
| 10:123149566:TCA:T | acceptor_loss | 0.9900 |
| 10:123149567:CA:C | acceptor_loss | 0.9900 |
| 10:123149568:A:G | acceptor_loss | 0.9900 |
| 10:123149569:G:GC | acceptor_loss | 0.9900 |
| 10:123148507:G:GT | donor_gain | 0.9800 |
| 10:123148645:GG:G | donor_gain | 0.9800 |
| 10:123148646:GG:G | donor_gain | 0.9800 |
| 10:123149568:A:AG | acceptor_gain | 0.9800 |
| 10:123149569:G:GG | acceptor_gain | 0.9800 |
| 10:123149569:GGT:G | acceptor_gain | 0.9800 |
| 10:123148596:C:CG | donor_gain | 0.9700 |
| 10:123148602:A:T | donor_gain | 0.9700 |
| 10:123148643:CTGGG:C | donor_loss | 0.9700 |
| 10:123148644:TGGG:T | donor_loss | 0.9700 |
| 10:123148647:GT:G | donor_loss | 0.9700 |
| 10:123148648:TAA:T | donor_loss | 0.9700 |
| 10:123149568:AG:A | acceptor_gain | 0.9700 |
| 10:123149569:GG:G | acceptor_gain | 0.9700 |
| 10:123149569:GGTA:G | acceptor_gain | 0.9700 |
| 10:123148341:G:GT | donor_gain | 0.9500 |
| 10:123148538:G:GT | donor_gain | 0.9500 |
| 10:123148596:C:G | donor_gain | 0.9500 |
AlphaMissense
1749 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 10:123149767:T:A | F156I | 1.000 |
| 10:123149767:T:C | F156L | 1.000 |
| 10:123149767:T:G | F156V | 1.000 |
| 10:123149768:T:C | F156S | 1.000 |
| 10:123149768:T:G | F156C | 1.000 |
| 10:123149769:T:A | F156L | 1.000 |
| 10:123149769:T:G | F156L | 1.000 |
| 10:123149781:G:C | Q160H | 1.000 |
| 10:123149781:G:T | Q160H | 1.000 |
| 10:123149792:T:A | L164H | 1.000 |
| 10:123149792:T:C | L164P | 1.000 |
| 10:123149792:T:G | L164R | 1.000 |
| 10:123149796:G:C | E165D | 1.000 |
| 10:123149796:G:T | E165D | 1.000 |
| 10:123149797:T:C | S166P | 1.000 |
| 10:123149803:T:A | F168I | 1.000 |
| 10:123149803:T:C | F168L | 1.000 |
| 10:123149803:T:G | F168V | 1.000 |
| 10:123149804:T:C | F168S | 1.000 |
| 10:123149804:T:G | F168C | 1.000 |
| 10:123149805:C:A | F168L | 1.000 |
| 10:123149805:C:G | F168L | 1.000 |
| 10:123149818:T:C | Y173H | 1.000 |
| 10:123149819:A:G | Y173C | 1.000 |
| 10:123149822:T:A | L174Q | 1.000 |
| 10:123149836:C:A | R179S | 1.000 |
| 10:123149846:T:C | L182P | 1.000 |
| 10:123149849:C:A | A183D | 1.000 |
| 10:123149858:T:C | L186P | 1.000 |
| 10:123149864:T:A | L188H | 1.000 |
dbSNP variants (sampled 300 via entrez): RS1001022112 (10:123150384 G>A), RS1001559774 (10:123150128 C>T), RS1001652693 (10:123148265 G>A,C), RS1001976564 (10:123149290 T>C), RS1002290976 (10:123147922 C>G), RS1002660096 (10:123147282 G>T), RS1002712614 (10:123147048 G>A), RS1004404254 (10:123146368 C>T), RS1004532803 (10:123150640 A>T), RS1004602520 (10:123149665 A>C,T), RS1004975484 (10:123150803 G>T), RS1005073336 (10:123150434 G>A), RS1005200290 (10:123148609 C>A), RS1005408077 (10:123147746 G>C), RS1005644373 (10:123148786 G>A)
Disease associations
OMIM: gene MIM:600647 | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
1 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST009391_677 | Metabolite levels | 6.000000e-06 |
EFO canonical traits (1, from GWAS)
| EFO ID | Trait name |
|---|---|
| EFO:0010506 | kynurenic acid measurement |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
22 total (human), top 22 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| entinostat | increases expression, affects cotreatment | 2 |
| belinostat | increases expression, affects cotreatment | 2 |
| Valproic Acid | increases expression, increases methylation | 2 |
| bisphenol F | increases expression | 1 |
| bisphenol A | increases expression | 1 |
| trichostatin A | decreases expression | 1 |
| arsenite | increases methylation | 1 |
| sodium arsenite | decreases expression | 1 |
| tetrabromobisphenol A | increases expression | 1 |
| 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide | affects cotreatment, increases expression | 1 |
| ICG 001 | decreases expression | 1 |
| dorsomorphin | affects cotreatment, increases expression | 1 |
| bisphenol S | increases methylation, affects cotreatment | 1 |
| 4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid | decreases expression | 1 |
| Fulvestrant | affects cotreatment, increases methylation | 1 |
| Vorinostat | affects cotreatment, increases expression | 1 |
| Panobinostat | affects cotreatment, increases expression | 1 |
| Benzo(a)pyrene | increases methylation, affects methylation | 1 |
| Carbamazepine | affects expression | 1 |
| Estradiol | affects expression | 1 |
| Methotrexate | increases expression | 1 |
| Niclosamide | increases expression | 1 |
Cellosaurus cell lines
2 cell lines: 2 embryonic stem cell
First 10 cell lines (id-ordered, not curated):
| Cellosaurus | Name | Category | Sex |
|---|---|---|---|
| CVCL_A2U4 | SEES3-1V human HMX2, clone1 | Embryonic stem cell | Male |
| CVCL_A2U5 | SEES3-1V human HMX2, clone2 | Embryonic stem cell | Male |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.